ARTICLE SUMMARY:
Current neuromodulation systems that are approved for chronic pain, overactive bladder and other conditions require surgical implantation, have bulky components under the surface of a patient’s skin, electronic leads that are prone to migration, and a limited battery life. Neuspera tackles these disadvantages and more with a wireless, mid-field powering method that requires only a tiny implant, inserted through a small puncture.
The field of bioelectronics—the use of electricity to treat diseases—holds much potential for large populations of patients with chronic diseases not well served by pharmaceuticals, because of side effects or drug resistance.
